{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:02:09Z","timestamp":1792461729623,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MK-5475"],"award-info":[{"award-number":["MK-5475"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.rmed.2022.107065","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T03:15:06Z","timestamp":1669691706000},"page":"107065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-1009","authenticated-orcid":false,"given":"Ednan K.","family":"Bajwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Cislak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Palcza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Denef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile","family":"Corcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5141-3452","authenticated-orcid":false,"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2022.107065_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.107065_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.107065_bib3","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2022.107065_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.107065_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1073\/pnas.44.10.1079","article-title":"The application of the Fick principle to the measurement of pulmonary blood flow","volume":"44","author":"Fritts","year":"1958","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.rmed.2022.107065_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","article-title":"Pulmonary arterial hypertension: combination therapy in practice","volume":"18","author":"Burks","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.rmed.2022.107065_bib7","series-title":"Product Information: VENTAVIS\u00ae (Iloprost) Inhalation Solution","year":"2017"},{"key":"10.1016\/j.rmed.2022.107065_bib8","series-title":"Product Information: Tyvaso\u00ae (Treprostinil) Inhalation Solution, for Oral Inhalation Only","year":"2017"},{"key":"10.1016\/j.rmed.2022.107065_bib9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2022.107065_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/COPD.S106480","article-title":"Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension","volume":"11","author":"Hajian","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122003304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122003304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T19:04:34Z","timestamp":1735758274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611122003304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":10,"alternative-id":["S0954611122003304"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2022.107065","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2022.107065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107065"}}